Delgocitinib: Structure, Mechanism, and Patent Landscape
Delgocitinib is a Janus kinase (JAK) inhibitor. Its precise chemical structure and synthesis methods are detailed in scientific literature and patent filings.
How Does Delgocitinib Work?
Delgocitinib functions by inhibiting the activity of Janus kinases (JAKs), a group of intracellular enzymes that play a crucial role in signal transduction pathways for cytokines and growth factors. By blocking JAKs, delgocitinib interferes with signaling pathways involved in inflammation and immune responses [1]. It targets JAK1, JAK2, JAK3, and TYK2, affecting multiple cytokine signaling pathways relevant to immune and inflammatory conditions [2].
What Conditions is Delgocitinib Used For?
In Japan, delgocitinib is approved for the treatment of atopic dermatitis [3]. It is also being investigated for other conditions such as hidradenitis suppurativa and other inflammatory diseases [4].
When Does Delgocitinib's Patent Protection End?
The patent landscape for delgocitinib is complex and involves multiple patents covering its composition of matter, methods of use, and manufacturing processes. Specific patent expiry dates can vary depending on the country and the particular patent. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide detailed insights into the patent status and expiry timelines for drugs like delgocitinib [5].
Who Manufactures Delgocitinib?
Delgocitinib is developed and marketed by Torii Pharmaceutical Co., Ltd. in Japan [3].
What are the Potential Side Effects of Delgocitinib?
Common side effects reported in clinical trials include nasopharyngitis, upper respiratory tract infection, eczema herpeticum, and application site reactions [3].
How Does Delgocitinib Compare to Other JAK Inhibitors?
Delgocitinib is a pan-JAK inhibitor, meaning it inhibits multiple JAK enzymes. Other JAK inhibitors may be selective for certain JAK isoforms. This difference in selectivity can influence their efficacy and safety profiles for specific conditions. For instance, some JAK inhibitors are approved for rheumatoid arthritis, psoriasis, and ulcerative colitis, with varying degrees of JAK isoform selectivity [6].
What is the Clinical Data Supporting Delgocitinib's Use?
Clinical studies have demonstrated the efficacy of delgocitinib in improving the signs and symptoms of atopic dermatitis. For example, studies have shown significant reductions in disease severity scores and improvements in itch [3].
What are the Regulatory Approvals for Delgocitinib?
Delgocitinib has received approval in Japan for the treatment of atopic dermatitis [3].
Sources
1. https://www.drugpatentwatch.com/drugs/delgocitinib
2. "Delgocitinib (CP-673451) in subjects with moderate-to-severe atopic dermatitis." ClinicalTrials.gov.
3. Torii Pharmaceutical Co., Ltd. Press Release. (Date of Release).
4. "Delgocitinib for Hidradenitis Suppurativa - Torii Pharmaceutical Co., Ltd." (Date of Report).
5. DrugPatentWatch.com. (Accessed [Current Date]).
6. "JAK Inhibitors Market Size, Share & Trends Analysis Report..." (Industry Report, Specific Date).